Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer

BJU International

Volumn 110, Issue 6B, 2012, Pages

  Pandha, Hardev ^a   Sorensen, Karen D ^b   Orntoft, Thorsten F ^b   Langley, Stephen ^c   Hoyer, Soren ^b   Borre, Michael ^b   Morgan, Richard ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Engrailed 2; prostate cancer; prostatectomy; urinary

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ENGRAILED 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; COHORT ANALYSIS; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; ORGAN WEIGHT; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE WEIGHT; PROSTATECTOMY; RELIABILITY; RISK ASSESSMENT; STORAGE TEMPERATURE; TUMOR VOLUME; URINALYSIS; URINE LEVEL;

AGED; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR BURDEN;

EID: 84865497735     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11208.x     Document Type: Article

References (27)

1. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J,. The prostate specific antigen era in the United States is over for PC: what happened in the last 20 years? J Urol 2004; 172: 1297-301 (Pubitemid 39249701)
2. Carvalhal GF, Daudi SN, Kan D, et al,. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology 2010; 76: 1072-6
3. Stamey TA, Freiha F, McNeal JE, Redwine EA, Whittemore AS, Schmid HP,. Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71 (Suppl.): 933-8 (Pubitemid 23049614)
4. Stamey TA, Kabalin JN, McNeal JE, et al,. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141: 1076-83 (Pubitemid 19124201)
5. Kattan MW, Eastham JA, Wheeler TM, et al,. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170: 1792-7 (Pubitemid 37254930)
6. Suardi N, Capitanio U, Chun FK, et al,. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer 2008; 113: 2068-62
7. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR,. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 2009; 181: 1628-34
8. Epstein JI, Chan DW, Sokoll LJ, et al,. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998; 160: 2407-11 (Pubitemid 29483051)
9. Wolters T, Roobol MJ, van Leeuwen PJ, et al,. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011; 185: 121-5
10. Morgan R, Boxall A, Bhatt A, et al,. Engrailed-2 (EN2): a tumour specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res 2011; 17: 1090-8
11. D'Amico AV, Whittington R, Malkowicz SB, et al,. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74 (Pubitemid 28445094)
12. Epstein JI,. Prognostic significance of tumour volume in radical prostatectomy and needle biopsy specimens. J Urol 2011; 186: 790-7
13. Epstein JI, Walsh PC, Carmichael M, Brendler CB,. Pathologic and clinical findings to predict tumour extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-74 (Pubitemid 24037911)
14. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT,. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994; 152: 1714-20 (Pubitemid 24322613)
15. Srigley JR, Amin MB, Bostwick DG, et al,. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000; 124: 1034-9 (Pubitemid 30602046)
16. Salomon L, Levrel O, Anastasiadis AG, et al,. Prognostic significance of tumour volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol 2003; 43: 39-44 (Pubitemid 36134314)
17. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM,. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281: 1395-400 (Pubitemid 29190217)
18. Ross AE, Loeb S, Landis P, et al,. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28: 2810-16
19. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT,. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004; 171: 1520-4 (Pubitemid 38365409)
20. Epstein JI, Walsh PC, Carter B,. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. JUrol 2001; 166: 1688-91 (Pubitemid 32953387)
21. Quintal MM, Meirelles LR, Freitas LL, et al,. Various morphometric measurements of cancer extent on needle prostatic biopsies: which is predictive of pathologic stage and biochemical recurrence following radical prostatectomy? Int Urol Nephrol 2011; 43: 697-705
22. Ploussard G, Durand X, Xylinas E, et al,. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011; 59: 422-9
23. Nakanishi H, Groskopf J, Fritsche HA, et al,. PCA3 molecular urine assay correlates with prostate cancer tumour volume: implication in selecting candidates for active surveillance. J Urol 2008; 179: 1804
24. Whitman EJ, Groskopf J, Ali A, et al,. PCA3 score before radical prostatectomy predicts extracapsular extension and tumour volume. J Urol 2008; 180: 1975-9
25. van Gils MP, Hessels D, Hulsbergen CA, et al,. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008; 68: 1215-22
26. Hessels D, van Gils MP, van Hooij O, et al,. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010; 70: 10-16
27. Auprich M, Chun FK, Ward JF, et al,. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 2011; 59: 96-105